Publikationen in Zusammenarbeit mit Forschern von National Taiwan University Hospital (1)

2022

  1. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 1, pp. 106-115